CTMX Stock Overview
An oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
CytomX Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.75 |
| 52 Week High | US$5.85 |
| 52 Week Low | US$1.04 |
| Beta | 1.08 |
| 1 Month Change | -60.50% |
| 3 Month Change | -35.66% |
| 1 Year Change | 2.34% |
| 3 Year Change | -75.11% |
| 5 Year Change | -83.01% |
| Change since IPO | -86.43% |
Recent News & Updates
Recent updates
We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now
May 09
CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling
May 02CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%
Apr 27CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
Apr 25CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%
Mar 05CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Jan 19There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise
Nov 26We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely
Nov 17Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 29Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?
Feb 13Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%
Nov 10CytomX Therapeutics to cut workforce by about 40%
Jul 13CytomX says phase 2 study of breast cancer antibody treatment met main goal
Jul 06Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Jun 08Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?
Feb 10CytomX: Pullbacks Are Opportunities
Dec 14CytomX: Solving A Critical Problem In The High-Value ADC Space
Sep 15We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate
Aug 11Checking In On CytomX Therapeutics
Jun 13Shareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being
Jun 10CytomX EPS beats by $0.06, misses on revenue
May 06Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 11%
Mar 25Shareholder Returns
| CTMX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 0.6% | -0.6% |
| 1Y | 2.3% | 6.3% | 22.4% |
Return vs Industry: CTMX underperformed the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: CTMX underperformed the US Market which returned 22.5% over the past year.
Price Volatility
| CTMX volatility | |
|---|---|
| CTMX Average Weekly Movement | 62.7% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CTMX's share price has been volatile over the past 3 months.
Volatility Over Time: CTMX's weekly volatility has increased from 33% to 63% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 121 | Sean McCarthy | www.cytomx.com |
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine.
CytomX Therapeutics, Inc. Fundamentals Summary
| CTMX fundamental statistics | |
|---|---|
| Market cap | US$132.46m |
| Earnings (TTM) | US$16.53m |
| Revenue (TTM) | US$119.18m |
8.2x
P/E Ratio1.1x
P/S RatioIs CTMX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTMX income statement (TTM) | |
|---|---|
| Revenue | US$119.18m |
| Cost of Revenue | US$0 |
| Gross Profit | US$119.18m |
| Other Expenses | US$102.65m |
| Earnings | US$16.53m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.21 |
| Gross Margin | 100.00% |
| Net Profit Margin | 13.87% |
| Debt/Equity Ratio | 0% |
How did CTMX perform over the long term?
See historical performance and comparison